Laddar...
Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada
BACKGROUND: Hereditary angioedema (HAE) is a rare autosomal dominant disease resulting in recurring episodes of swelling, leading to considerable patient morbidity and mortality. Lanadelumab is a plasma kallikrein inhibitor that is approved as 1st line therapy in Canada for long term prophylaxis of...
Sparad:
| I publikationen: | Allergy Asthma Clin Immunol |
|---|---|
| Huvudupphovsmän: | , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BioMed Central
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8306280/ https://ncbi.nlm.nih.gov/pubmed/34301329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-021-00579-6 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|